Blockchain Registration Transaction Record

AI-Powered Blood Tests Revolutionize Heart Disease Detection

Cardio Diagnostics Holdings uses AI, epigenetics, and genetics in blood tests Epi+Gen CHD and PrecisionCHD to detect coronary heart disease and heart attack risk, addressing a growing $1.4 trillion market.

This news matters because cardiovascular disease remains the leading cause of death globally, yet many cases go undetected until it's too late. Cardio Diagnostics' AI-driven tests offer a noninvasive, blood-based method to identify heart disease and heart attack risk earlier, potentially saving lives and reducing healthcare costs. With reimbursement secured and international expansion underway, these tests could become widely accessible, empowering patients and doctors with precision diagnostics that outperform conventional tools.